Two neuropeptides, two distinct mechanisms, and what the research says about their role in cognitive and neurological studies.
Most peptide research clusters around metabolic, recovery, or hormonal pathways. The cognitive category is smaller, but the compounds within it are among the most studied neuropeptides in the literature. Selank and Semax were both developed in Russia, both have decades of published research behind them, and both operate through mechanisms that don't overlap. That distinction is what makes the stack interesting from a research design perspective.
Selank is a synthetic heptapeptide analogue of tuftsin, a naturally occurring tetrapeptide produced by the spleen. Tuftsin (Thr-Lys-Pro-Arg) is an immunomodulatory peptide, but Selank was designed around a modified version (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with a focus on central nervous system activity. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied there since the 1990s.
The primary research interest in Selank has been its anxiolytic profile. In animal models, Selank consistently reduces anxiety-associated behaviors without the sedation or motor impairment seen with benzodiazepine compounds. This distinction drove a significant portion of early research, because the classic anxiolytic mechanism (GABA-A receptor potentiation) comes with well-documented side effects on cognition and coordination. Selank appears to produce its anxiolytic effects through a different pathway.
Proposed mechanisms in the research literature include interaction with the enkephalinase enzyme system (which breaks down endogenous opioids), modulation of serotonin and dopamine metabolism, and possible GABA-ergic activity at a subtype level distinct from benzodiazepine binding sites. None of these are definitively established. What is consistent across the published animal model data is the behavioral outcome: reduced anxiety response with preserved or improved cognitive performance.
Beyond the anxiolytic profile, Selank research has documented effects on memory consolidation and learning in rodent models. The compound appears to influence the expression of brain-derived neurotrophic factor (BDNF) in some studies, and several papers from the Russian literature report improved performance on spatial memory tasks in both normal and stressed animal subjects.
It's worth noting that most of the long-form Selank research comes from Russian institutional publications. The compound hasn't been studied as extensively in Western academic settings, which limits independent replication of some findings. Researchers should factor this into how they weight specific claims from the literature.
Semax is a synthetic analogue of adrenocorticotropin (ACTH) fragment 4-10, specifically the sequence Met-Glu-His-Phe-Pro-Gly-Pro. ACTH(4-10) was identified as a fragment with neurotrophic and cognitive-enhancing properties in early research, but its native form is rapidly degraded in the body. Semax was developed as a stable version for research and clinical investigation, and like Selank, originated at the Institute of Molecular Genetics.
The most significant documented effect of Semax in research models is BDNF upregulation. Brain-derived neurotrophic factor is a protein that supports the survival of existing neurons and promotes the growth and differentiation of new neurons and synapses. It's a critical factor in synaptic plasticity, memory formation, and neurological recovery after injury. In rodent and cell culture studies, Semax increases BDNF expression in the hippocampus and prefrontal cortex, the regions most associated with learning, memory, and executive function.
The neuroprotective angle is where Semax research is most extensive. Multiple studies have looked at Semax in ischemia models, where its ability to reduce neuronal cell death and improve functional recovery after experimental stroke has been documented across several independent research groups. The mechanism proposed involves upregulation of both BDNF and nerve growth factor (NGF), alongside effects on oxidative stress markers and inflammatory signaling in neural tissue.
In healthy animal models (not just injury or ischemia contexts), Semax has shown effects on learning speed, working memory, and attention measures. Some of the more interesting research involves the timeline of effects: unlike compounds that require weeks of administration to show measurable outcomes, Semax studies often report cognitive effects within hours or days of administration, which suggests a relatively direct mechanism rather than slow structural changes.
The nasal route is standard in most published Semax protocols. The olfactory pathway provides relatively direct access to brain tissue, which is why intranasal administration is used for several neuropeptides where peripheral administration produces inconsistent central uptake. Lumé's Selank/Semax stack is lyophilized, allowing researchers to reconstitute and administer via this route per their specific protocol design.
The Selank/Semax combination is studied together because the compounds address different aspects of cognitive and neurological function without mechanistic redundancy.
Selank's primary research profile is anxiolytic and mood-stabilizing, with secondary cognitive effects. Semax's primary profile is neuroprotective and neurotrophic, with BDNF and NGF upregulation driving most of its documented effects. In a research protocol studying cognitive performance under stress, for example, Selank addresses the stress-anxiety component while Semax addresses the underlying neurotrophic support for learning and memory consolidation.
The combination also allows researchers to study whether the two mechanisms produce additive or synergistic outcomes in cognition models, which is an active area of interest in neuropeptide research. Most published stack protocols use both compounds at comparable doses, which is reflected in the Lumé formulation (10mg/10mg, $120).
Both compounds are typically administered intranasally in published protocols, using the olfactory route for central uptake. Reconstitution in sterile water or BAC water is standard. Because both peptides are relatively short and structurally simpler than longer-chain peptides like GLP-3 Reta, they reconstitute quickly and fully in solution with minimal agitation.
Standard research protocols for the Selank/Semax stack document dosing cycles rather than continuous administration. Protocols typically run in blocks with off periods, though the optimal cycle structure varies by research objective. Refer to the published literature from the Institute of Molecular Genetics and subsequent independent groups for specific protocol designs.
The cognitive peptide category doesn't get as much mainstream attention as metabolic or recovery research. But the depth of the published literature on Selank and Semax, spanning decades and multiple independent groups, puts them on the same empirical footing as many better-known compounds.
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. These statements and products are not intended to diagnose, treat, cure, or prevent any disease. Lumé Longevity LLC is a chemical supplier and is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Not an outsourcing facility as defined under 503B. All products are sold for research, laboratory, or analytical purposes only.